Matter of Pletcher v New York State Gaming Commission
Categories
Attorneys and Parties
Brief Summary
This case concerns medication regulation in thoroughbred horse racing, specifically whether a trainer may be disciplined when a postrace test detects Meloxicam, a nonsteroidal anti-inflammatory drug, under 9 NYCRR 4043.2(d) [rule allowing only three specified nonsteroidal anti-inflammatory drugs to be administered until 48 hours before post time] and 9 NYCRR 4043.2(h) [rule barring administration of any other drugs or medications within one week of scheduled post time].
Supreme Court denied the Gaming Commission's motion to dismiss for failure to join necessary parties and transferred the CPLR article 78 proceeding to the Appellate Division under CPLR 7804(g) [procedure requiring transfer where a substantial evidence issue is raised].
Nothing was overturned. The Appellate Division confirmed the Gaming Commission's determination, upheld the 10-day suspension and $1,000 fine, and dismissed the petition.
The court held that the Gaming Commission rationally interpreted 9 NYCRR 4043.2(d) to mean that a positive postrace finding of Meloxicam itself established a prima facie violation, even without direct proof of administration within seven days, because Meloxicam is not one of the three permitted nonsteroidal anti-inflammatory drugs and its administration timing is difficult to prove through testing. The determination was also supported by substantial evidence, and petitioner failed to rebut the trainer-responsibility presumption under 9 NYCRR 4043.4 [trainer responsibility rule making the trainer responsible for a horse's positive drug test].
Background
Todd A. Pletcher trained Forte, the horse that finished first in the eleventh race at Saratoga Race Course on September 5, 2022. Postrace blood and urine samples tested positive for Meloxicam, and split-sample testing by Texas A&M Veterinary Medical Diagnostic Laboratory confirmed the result. The state steward suspended Pletcher from thoroughbred racing for 10 days and imposed a $1,000 fine. On administrative appeal, the Hearing Officer found that Meloxicam's presence in the horse violated 9 NYCRR 4043.2(d) and that Pletcher was responsible under 9 NYCRR 4043.4. The Gaming Commission adopted that recommendation. Pletcher then brought this CPLR article 78 proceeding, arguing principally that the regulation required proof that Meloxicam had been administered within seven days before the race and that the agency's interpretation was irrational, unsupported by substantial evidence, and procedurally unfair.
Lower Court Decision
Supreme Court rejected the Gaming Commission's threshold argument that the petition should be dismissed for failure to join necessary parties. It then transferred the proceeding to the Appellate Division because the petition raised a substantial evidence challenge to an administrative determination made after a hearing.
Appellate Division Reversal
The Appellate Division did not disturb Supreme Court's transfer order. On the merits, it confirmed the Gaming Commission's determination and dismissed the petition. The court held that the agency's reading of 9 NYCRR 4043.2(d) was rational and entitled to deference: because the rule permits only three named nonsteroidal anti-inflammatory drugs and Meloxicam is not among them, a positive postrace test for Meloxicam was enough to establish a prima facie violation, without separate direct proof of when the drug was administered. The court further held that the laboratory evidence constituted substantial evidence and that petitioner's alternative contamination theories were speculative and insufficient to rebut the presumption of responsibility. It also rejected petitioner's due process challenge to intervention at the administrative hearing and found several other arguments unpreserved or meritless.
Legal Significance
The decision is a first-impression ruling on the interaction between 9 NYCRR 4043.2(d) and 9 NYCRR 4043.2(h). It confirms that, in the context of New York thoroughbred racing regulation, the Gaming Commission may treat the postrace presence of a non-permitted nonsteroidal anti-inflammatory drug as sufficient proof of a violation of the nonsteroidal anti-inflammatory drug rule, even where the agency cannot directly prove the time of administration. The case also reinforces judicial deference to an agency's reasonable interpretation of its own regulations and the strength of the trainer-responsibility presumption under 9 NYCRR 4043.4.
In New York thoroughbred racing, if a postrace test detects Meloxicam, the Gaming Commission may discipline the trainer based on the drug's presence alone under 9 NYCRR 4043.2(d), and the trainer must come forward with substantial non-speculative proof to overcome the presumption of responsibility.